Michelle Hoffman

See Michelle Hoffman's bio page.

At a time when the industry is struggling with innovation, it might do well to learn a lesson from a few great innovators.

A report commissioned by FDA evaluates the QbD program.

Are biosimilars the next big thing or just the next big bubble?

Which route will we take to arrive at a national stem-cell policy?

Those who doubt there's faith in science, should check out our annual Bioprocessing Survey.

Results from our annual survey. This article contains online bonus material and is part of a special issue on Bioprocessing and Sterile Manufacturing.

Research and development may be headed for divorce.

Follow-ons were all the rage at this year's JP Morgan Healthcare Conference.

Capable of great works, pharma as a whole still yields to the lesser angels of its nature.